ADIL Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -24.01%, SMA50 -48.18%, SMA200 -71.31%). The stock’s 14-day RSI is 19.19 (weak momentum), while the ATR of 0.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -91.64% below its high and over 11.45% above its low. Average 10-day trading volume of 31.32 thousand shares is below the 3-month average of 484.32 thousand, indicating normal recent market interest.

Adial Pharmaceuticals, Inc. has 2.19 million shares outstanding. The public float is 1.40 million shares, elevated short interest at 10.61% of float. This equals 230.98 thousand shares. The short ratio is 0.21 days. Institutional investors hold 29.15% of the float. Insiders own 4.32%. Stilley William B. III holds 937.65 thousand shares, Coastlands Capital LP has 388.31 thousand shares and Johnson Bankole A. has 148.25 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Adial Pharmaceuticals, Inc. generated EPS of -$23.15 over the past year. Five-year average earnings growth is 34.05%. Wall Street analysts project EPS growth of 65.97% annually over the next five years. The latest quarter delivered EPS of -$1.48. The next quarter is forecast at -$2.13. Next year's EPS is expected at $73.26. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $1.50. The high target offers 118.98% upside. The low target suggests -45.26% downside. The mean target is $3.75. This offers 36.86% upside. Adial Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 08, 2026, missed forecasts by -45.79%. The prior quarter beat by -13.81%. Over the last six quarters, Apple has recorded several small beats. These include -60.53% in March 04, 2025.

Adial Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.80. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Adial Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.92%, with price expected at $2.82 by August 04, 2026, within a range of $2.61 to $3.04 3-Month Outlook: Projected rise of 100.36%, reaching $5.49 by October 19, 2026, with a range of $5.03 to $5.99. 1-Year Outlook: Projected loss of -86.86%, with price at $0.36 by July 21, 2027, within a range of $0.00 to $2.24.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) shares are flat -1.68% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Adial Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.28. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.62, suggesting 68.61% upside. Our AI forecast model points to short-term strength (2.92% over two weeks), a medium-term rise (100.36% over three months), and a longer-term loss (-86.86% over one year), with expected trading ranges indicating moderate volatility.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) closed at $2.81 USD, gaining $0.07 (2.55%) from the previous close of $2.74. The stock is currently mid-range between its 52-week high and low $1.31 and $19.00. With a market capitalization of about $2.70 million, Adial Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.43). Key stats such as the average daily volume over the past year has been around 468.92 thousand shares, volume is running light vs its 52-week average. Headquartered in Glen Allen, VA, Adial Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Cary John Claiborne, the company employs approximately 5 people and listed since July 27, 2018. Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders.

Adial Pharmaceuticals, Inc. trades at a P/E ratio of -0.28, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.0 suggesting the stock is closer to book value. The P/FCF stands at -0.4, also above market averages.